CHRONIC MYELOMONOCYTIC LEUKEMIA

This study tests two drugs, vorinostat and azacitidine, together in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). The goal is to find the safest dose and see how well the combination works at controlling the disease. About 135 adults with these bloo…

This study tests whether the oral drug Inqovi can reduce the chance of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) coming back after a stem cell transplant. About 22 adults who have had a reduced-intensity transplant will take Inqovi as maintenance th…

This study tests a combination of three drugs (azacitidine, venetoclax, and pevonedistat) in adults with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) that is either related to prior cancer treatment or developed from other blood disorders. The goal is to fin…

This study tests whether giving two chemotherapy drugs (clofarabine and melphalan) before a donor stem cell transplant can help prevent leukemia from returning in patients whose cancer is in remission. The approach aims to kill any remaining cancer cells and stop the immune syste…

This study tests two drugs together for people with chronic myelomonocytic leukemia (CMML), a rare blood cancer. One drug is a targeted therapy that seeks out and kills cancer cells, while the other is a standard chemotherapy. The goal is to find the best dose and see if the comb…

This study looks at whether a special health check-up for older adults (age 60+) can help doctors choose the safest stem cell transplant approach for blood cancers like leukemia or myelodysplastic syndrome. The check-up measures thinking, mobility, mood, and nutrition to tailor t…

This study tests whether adding another drug (lenalidomide or vorinostat) to the standard chemotherapy azacitidine works better than azacitidine alone for people with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). About 282 adults took part…

This study was designed to test whether adding olutasidenib to a standard chemotherapy drug could help control certain blood cancers (MDS, CMML, and MPN) in people with an IDH1 gene mutation. The study was withdrawn before enrolling any participants, so no results are available. …

This study offers continued treatment with the drug ASTX727 to adults with acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndromes who were already benefiting from it in earlier studies. The main goal is to gather long-term safety information. About …

This study tested whether adding the drug veliparib to standard chemotherapy helps people with advanced blood cancers like acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). About 25 adults took part. The goal was to see if the combination improved response …

This early-phase trial tests a new treatment for people whose blood cancer (like AML or MDS) has returned after a stem cell transplant. The treatment combines a special donor cell infusion with an immunotherapy drug (ipilimumab) to fight the cancer. The main goal is to find the s…

This study tested a modified approach to prevent and treat cytomegalovirus (CMV) infection in 153 people with blood cancers who had a donor stem cell transplant. The goal was to see if delaying or adjusting anti-CMV therapy could still keep patients safe while reducing unnecessar…

This study tests whether adding epoetin alfa to lenalidomide helps people with myelodysplastic syndrome (MDS) and anemia better than lenalidomide alone. About 247 adults with low- or intermediate-risk MDS and low red blood cell counts took part. The main goal was to see if the co…

This study is for people newly diagnosed with a specific type of acute myeloid leukemia (AML) linked to prior cancer treatment or other bone marrow disorders. It tests whether adding the drug pomalidomide to standard chemotherapy can improve treatment results. About 50 adults wil…

This study tests a combination of two chemotherapy drugs (CPX-351 and gemtuzumab ozogamicin) in about 50 adults with acute myeloid leukemia (AML) that has returned or not responded to treatment, or with high-risk myelodysplastic syndrome (MDS). The goal is to see if the combinati…

This study tests a new drug called bexmarilimab combined with standard treatments for people with certain blood cancers (MDS, CMML, or AML). The goal is to find a safe dose and see if the combination helps control the disease. About 181 adults will take part, and the study is cur…

This study tests a combination of two drugs, azacitidine and quizartinib, in 30 adults with certain blood cancers (MDS, MDS/MPN, CMML) that have specific gene mutations (FLT3 or CBL). The goal is to find the best dose and see how well the drugs control the cancer. This is not a c…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease. About 313 adults with various blood cancers…

This study tests a combination of two drugs—guadecitabine and atezolizumab—in people with myelodysplastic syndrome or chronic myelomonocytic leukemia that has spread, returned, or not responded to prior treatment. The goal is to find the best dose and see if the combo can shrink …

This study tests two drugs, venetoclax and ASTX727, in people with high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia who haven't had treatment yet. The goal is to see how well the combination works at controlling the cancer and what side effects it causes. Abo…

This phase 2 trial tests whether adding venetoclax to the drug ASTX727 works better than ASTX727 alone for people with chronic myelomonocytic leukemia or related bone marrow cancers with too many immature cells. About 132 adults will receive either the combination or ASTX727 alon…

This study tests whether the drug ruxolitinib can help people with chronic myelomonocytic leukemia (CMML), a rare blood cancer. About 29 adults will receive the drug to see if it improves blood counts, shrinks the cancer, or keeps it stable. The goal is to control the disease and…

This study was designed to learn how the protein calprotectin might change blood stem cells in people with severe COVID-19 or certain blood cancers. Researchers planned to compare stem cells from patients with severe or moderate COVID-19, those with chronic myeloid malignancies, …